Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.78 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3215158 | 1.00 | LSS (0.78) | LSSGLANPC1RAB9ACHRNA7 | |
| Hydrochloric Acid SCHEMBL9469303 | 0.98 | LSS (0.76) | LSSGLANPC1RAB9ACHRNA7 | |
| SCHEMBL8040198 | 0.89 | LSS (1.00) | LSSGLANPC1RAB9ACHRNA7 | |
| Hydrochloric Acid SCHEMBL8988213 | 0.87 | LSS (0.97) | LSSGLANPC1RAB9ACHRNA7 | |
| SCHEMBL5390772 | 0.86 | LSS (0.60) | LSSCHRNA7 | |
| SCHEMBL14039989 | 0.83 | CHRNA7 (0.67) | LSSGLANPC1RAB9ACHRNA7 | |
| SCHEMBL1849257 | 0.83 | LSS (0.57) | LSSCHRNA7 | |
| SCHEMBL2323165 | 0.83 | LSS (0.57) | LSSCHRNA7 | |
| SCHEMBL1542743 | 0.83 | LSS (0.57) | LSSCHRNA7 | |
| SCHEMBL6941982 | 0.83 | LSS (0.57) | LSSCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | ARGENTA DISCOVERY LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| WO-2010018352-A1 | HETEROCYCLIC COMPOUNDS USED IN THE TREATMENT OF DISEASES WHERE ENHANCED M3 RECEPTOR ACTIVATION IS IMPLICATED | ARGENTA DISCOVERY LIMITED (GB) | 2010-02-18 | — | — | WO | disclosed |
| EP-2121688-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | Argenta Discovery Ltd (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008099186-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | CHRM2, CHRM3, CHRM1 | LSS 4700/4885GLA 3206/4885NPC1 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.